Imitate Inc. closes $82M Series E to money expansion of ‘organ-on-a-chip’ items
Emulate Inc., a biotech company concentrated on developing “organ-on-a-chip” technology, closed an $82 million Series E round on Tuesday. This latest round is meant to formulate a massive financial investment in a “roadmap” for developing design organ systems created to fit drug makers’ needs and bring the idea of an organ-on-a-chip into usage in the lab. […] An organ-on-a-chip is quite much precisely what it sounds like: It’s a recreation of a human organ (or system of human organs) scaled down into a tiny piece of hardware about the size of a AA battery. This most recent Series E round, led by Northpond Ventures and Perceptive Advisors, is part of Emulate’s plan to invest more greatly in R&D, and produce specific organ-on-a-chip applications that they have actually homed in on through conversations with drug companies. A lot of that development will depend on the potential for an organ-on-a-chip to interfere with the preclinical side of the drug testing procedure. Still, the field of organ-on-a-chip research is relatively new. …
Recent Comments